Long term follow-up of Palivizumab administration in children born at 29 –32 weeks of gestation

Severe respiratory syncytial virus (RSV) bronchiolitis requiring hospitalization induces long term immunological and respiratory abnormalities. The long-term immunomodulation effect of Palivizumab (RSV monoclonal antibody) prophylaxis and its impact on the development of asthma remain controversial. Our aim was to evaluate airway hyper-reactivity, systemic inflammatory markers, allergic parameters and respiratory morbidity, 5-7 years following Palivizumab administration to children born at 29 –32 weeks of gestation (WGA).

Source: Respiratory Medicine - March 18, 2019 Category: Respiratory Medicine Authors: Ronen Bar Yoseph, Julie Haddad, Monnera Hanna, Irena Kessel, Amir Kugelman, Fahed Hakim, Lea Bentur Source Type: research